NDRG2 and nonpapillary renal cell carcinoma: It is reported that the loss of pVHL is associated with modulations of the TGF-β1, whose expression is correlated to poor prognosis in CCRCC [36-39], while NDRG2 can antagonize TGF-β1 mediated tumor cell invasion in hepatocellular carcinomas [40].